CovalentInDB: a comprehensive database facilitating the discovery of covalent inhibitors

Abstract Inhibitors that form covalent bonds with their targets have traditionally been considered highly adventurous due to their potential off-target effects and toxicity concerns. However, with the clinical validation and approval of many covalent inhibitors during the past decade, design and discovery of novel covalent inhibitors have attracted increasing attention. A large amount of scattered experimental data for covalent inhibitors have been reported, but a resource by integrating the experimental information for covalent inhibitor discovery is still lacking. In this study, we presented Covalent Inhibitor Database (CovalentInDB), the largest online database that provides the structural information and experimental data for covalent inhibitors. CovalentInDB contains 4511 covalent inhibitors (including 68 approved drugs) with 57 different reactive warheads for 280 protein targets. The crystal structures of some of the proteins bound with a covalent inhibitor are provided to visualize the protein–ligand interactions around the binding site. Each covalent inhibitor is annotated with the structure, warhead, experimental bioactivity, physicochemical properties, etc. Moreover, CovalentInDB provides the covalent reaction mechanism and the corresponding experimental verification methods for each inhibitor towards its target. High-quality datasets are downloadable for users to evaluate and develop computational methods for covalent drug design. CovalentInDB is freely accessible at http://cadd.zju.edu.cn/cidb/.

[1]  M. Potashman,et al.  Covalent modifiers: an orthogonal approach to drug design. , 2009, Journal of medicinal chemistry.

[2]  Cathy H. Wu,et al.  UniProt: the Universal Protein knowledgebase , 2004, Nucleic Acids Res..

[3]  Nicholas B Rego,et al.  3Dmol.js: molecular visualization with WebGL , 2014, Bioinform..

[4]  Richard Lonsdale,et al.  Expanding the Armory: Predicting and Tuning Covalent Warhead Reactivity , 2017, J. Chem. Inf. Model..

[5]  David S. Goodsell,et al.  RCSB Protein Data Bank: biological macromolecular structures enabling research and education in fundamental biology, biomedicine, biotechnology and energy , 2018, Nucleic Acids Res..

[6]  F. McCormick,et al.  RAS-targeted therapies: is the undruggable drugged? , 2020, Nature Reviews Drug Discovery.

[7]  The Uniprot Consortium UniProt: the universal protein knowledgebase , 2018, Nucleic acids research.

[8]  G. Keserű,et al.  Covalent fragment libraries in drug discovery. , 2020, Drug discovery today.

[9]  Igor V. Tetko,et al.  Application of Associative Neural Networks for Prediction of Lipophilicity in ALOGPS 2.1 Program , 2002, J. Chem. Inf. Comput. Sci..

[10]  S. Laufer,et al.  Emerging and Re-Emerging Warheads for Targeted Covalent Inhibitors: Applications in Medicinal Chemistry and Chemical Biology. , 2018, Journal of medicinal chemistry.

[11]  Noel S. Wilson,et al.  Covalent binders in drug discovery. , 2019, Progress in medicinal chemistry.

[12]  P. Bourne,et al.  Determining Cysteines Available for Covalent Inhibition Across the Human Kinome. , 2017, Journal of medicinal chemistry.

[13]  David S. Wishart,et al.  DrugBank 5.0: a major update to the DrugBank database for 2018 , 2017, Nucleic Acids Res..

[14]  Evan Bolton,et al.  PubChem 2019 update: improved access to chemical data , 2018, Nucleic Acids Res..

[15]  E. Myers,et al.  Basic local alignment search tool. , 1990, Journal of molecular biology.

[16]  Han Zhang,et al.  Ranking Reversible Covalent Drugs: From Free Energy Perturbation to Fragment Docking , 2019, J. Chem. Inf. Model..

[17]  Andrew R. Leach,et al.  ChEMBL: towards direct deposition of bioassay data , 2018, Nucleic Acids Res..

[18]  J. Falgueyret,et al.  The discovery of odanacatib (MK-0822), a selective inhibitor of cathepsin K. , 2008, Bioorganic & medicinal chemistry letters.

[19]  R. Lonsdale,et al.  Structure-based design of targeted covalent inhibitors. , 2018, Chemical Society reviews.

[20]  N. Gray,et al.  Recent Advances in Selective and Irreversible Covalent Ligand Development and Validation. , 2019, Cell chemical biology.

[21]  Kai Zhu,et al.  Docking Covalent Inhibitors: A Parameter Free Approach To Pose Prediction and Scoring , 2014, J. Chem. Inf. Model..

[22]  F. Lombardo,et al.  Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings , 1997 .

[23]  William L Todsen ChemDoodle 6.0 , 2014, J. Chem. Inf. Model..

[24]  Wesley M. Botello-Smith,et al.  Can Relative Binding Free Energy Predict Selectivity of Reversible Covalent Inhibitors? , 2017, Journal of the American Chemical Society.

[25]  Adrian Whitty,et al.  The resurgence of covalent drugs , 2011, Nature Reviews Drug Discovery.

[26]  Peng Ding,et al.  cBinderDB: a covalent binding agent database , 2017, Bioinform..

[27]  A. Olson,et al.  Proteome-wide covalent ligand discovery in native biological systems , 2016, Nature.

[28]  Matthew Grist,et al.  Structure- and reactivity-based development of covalent inhibitors of the activating and gatekeeper mutant forms of the epidermal growth factor receptor (EGFR). , 2013, Journal of medicinal chemistry.